- Analysis of 166 Hypogonadal Oligospermic Men: 71.1% exhibited an increase in sperm concentration following clomiphene citrate therapy, while 28.9% experienced a paradoxical decline
- Biochemical vs. Spermatogenic Discordance: Serum total testosterone normalized (>= 3.5 ng/mL) in 91% of patients, but hormonal normalization did not correlate with semen improvement
- Modest Absolute Improvements: Median sperm concentration rose from 4.0 to 5.6 million/mL; only 13.3% achieved normozoospermia (>= 16 million/mL)
- Clinical Imperative: Semen analysis must be re-evaluated at 3 months; serum testosterone cannot serve as a surrogate marker for sperm production
When male fertility testing identifies both low sperm counts (oligospermia) and low serum testosterone (hypogonadism), clinicians frequently prescribe clomiphene citrate. While traditionally known as a female ovulation-inducing agent, clomiphene is widely used off-label in male reproductive medicine to stimulate endogenous testosterone production while preserving testicular spermatogenesis.
However, a study published in the World Journal of Men’s Health (June 2026) reveals that while clomiphene reliably elevates serum testosterone, its effect on sperm parameters is highly heterogeneous, with nearly 3 out of 10 men experiencing a paradoxical reduction in sperm concentration.
Study Design and Treatment Protocol
Researchers from Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital in Italy evaluated 166 men presenting with hypogonadal oligospermia, defined by:
- Baseline total testosterone < 3.5 ng/mL
- Baseline sperm concentration < 15 million/mL
All patients were treated with clomiphene citrate 50 mg daily for a minimum of 3 months (median treatment duration: 4 months).
Endocrine Mechanism: Why Clomiphene Is Prescribed Over Exogenous Testosterone
Exogenous testosterone therapy (injections, gels, or pellets) triggers strong negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis. This suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, reducing intratesticular testosterone and frequently resulting in severe azoospermia. For this reason, exogenous testosterone is strictly contraindicated in men seeking fertility.
Clomiphene citrate acts as a Selective Estrogen Receptor Modulator (SERM):
- It competitively blocks estrogen receptors at the level of the hypothalamus and anterior pituitary gland.
- This inhibits endogenous estrogen negative feedback, stimulating the pulsatile release of Gonadotropin-Releasing Hormone (GnRH).
- Increased GnRH stimulates pituitary secretion of LH (which acts on Leydig cells to produce endogenous intratesticular testosterone) and FSH (which acts on Sertoli cells to support spermatogenesis).
Hormonal vs. Semen Parameter Outcomes
| Parameter | Baseline (Pre-Treatment) | Post-Treatment (Median 4 Months) | Clinical Outcome / Statistical Result |
| Total Testosterone (Median) | 2.9 ng/mL | 4.6 ng/mL | 91% (151/166) achieved normalization (>= 3.5 ng/mL) |
| Sperm Concentration (Median) | 4.0 million/mL | 5.6 million/mL | Statistically significant overall increase (+1.6 million/mL) |
| Sperm Concentration Responders | — | — | 71.1% (118/166) showed an increase |
| Paradoxical Non-Responders | — | — | 28.9% (48/166) showed a decline (median drop: -3.3 million/mL) |
| Normozoospermia (>= 16 M/mL) | 0% (Baseline entry criteria) | 13.3% (22/166) | Only 1 in 8 achieved fully normal concentrations |
| Total Motile Sperm Count (TMSC) | 1.3 million | 1.7 million | Modest median gain; 22.9% achieved TMSC >= 5 million |
| Sperm Motility & Morphology | Baseline impairment | No significant change | No statistically significant improvement |
The Decoupling of Testosterone and Spermatogenesis
A central finding of this trial was the complete lack of correlation between endocrine normalization and semen parameter improvement:
- Among men whose serum testosterone successfully normalized to >= 3.5 ng/mL, 71% exhibited an increase in sperm concentration.
- Among men whose testosterone failed to reach normal levels, 73% still exhibited an increase in sperm concentration.
Elevated serum testosterone on a follow-up blood test does not guarantee that sperm production has improved. Intratesticular regulatory dynamics and Sertoli cell responsiveness operate independently of circulating blood hormone concentrations.
Statistical vs. Clinical Efficacy: The “4.0 to 5.6 Million” Threshold
While a rise in median sperm concentration from 4.0 to 5.6 million/mL represents an approximate 40% relative increase, the absolute median gain was only 1.6 million/mL:
- For a man with severe oligospermia, gaining 1 to 2 million sperm per mL is rarely sufficient to transition a couple from requiring In Vitro Fertilization / Intracytoplasmic Sperm Injection (IVF-ICSI) to achieving natural conception or Intrauterine Insemination (IUI).
- Only 22.9% of patients reached a Total Motile Sperm Count (TMSC) >= 5 million—a common clinical threshold for IUI eligibility.
Predictors and Clinical Monitoring
The research team analyzed clinical markers (age, BMI, testicular volume, baseline LH, FSH, testosterone, and estradiol) to determine which patients respond favorably:
- Baseline Estradiol (E2): Higher baseline estradiol levels correlated with greater odds of testosterone normalization, likely reflecting higher aromatase activity where hypothalamic estrogen blockade exerts maximal leverage.
- Baseline Sperm Concentration: Men with lower starting concentrations were statistically more likely to show relative increases, whereas men with higher baseline counts experienced higher rates of paradoxical decline.
- Unpredictability of Decline: Standard baseline hormone panels could not reliably predict which individuals would experience the 28.9% paradoxical decline in sperm count.
Because the human spermatogenic cycle takes approximately 70 to 75 days, a repeat semen analysis at 3 months post-initiation is clinically mandatory. Relying solely on serum testosterone blood work risks missing patients whose sperm counts are declining on therapy.
Clinical Guidelines Context (AUA / ASRM)
Current joint guidelines from the American Urological Association (AUA) and the American Society for Reproductive Medicine (ASRM) state:
- Contraindication: Exogenous testosterone monotherapy should not be prescribed to men actively seeking conception.
- Off-Label SERM Utilization: SERMs (such as clomiphene citrate), aromatase inhibitors, or human chorionic gonadotropin (hCG) may be considered in infertile men with low serum testosterone to support endogenous spermatogenesis.
- Realistic Expectations: Clinicians must counsel patients that the reproductive benefits of empiric SERM therapy in idiopathic or mild male-factor infertility are modest compared to definitive assisted reproductive technologies.
Summary
Clomiphene citrate is an effective medical option for raising endogenous testosterone in hypogonadal men while avoiding the contraceptive effects of exogenous testosterone.
However, its effect on sperm production is variable: while 71% of patients experience modest increases in sperm concentration, nearly 29% experience paradoxical declines. Successful management requires routine follow-up semen analyses at 3 months rather than relying on blood testosterone levels alone.
Medical Source & Study Information
- Journal: The World Journal of Men’s Health (Published online June 5, 2026)
- Study Title: Outcomes and Predictors in Hypogonadal Oligospermic Men Treated with Clomiphene Citrate
- Lead Institutions: Unit of Urology / Division of Experimental Oncology, URI, IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University, Milan, Italy
- DOI: 10.5534/wjmh.250371
※ This article was synthesized based on the clinical trial published in the World Journal of Men’s Health (2026) alongside male infertility practice guidelines from the AUA and ASRM. It does not replace individualized clinical diagnosis or medical care, and specific pharmacological decisions should always be made in consultation with a qualified urologist or reproductive endocrinologist.
※ The images associated with this article were generated using generative AI (ChatGPT, OpenAI) as illustrative visual references and do not depict real individuals.